卢煜明开启NIPT新时代,实现无创单基因遗传病检测

2016-12-20 生物探索 生物探索

导读 随着技术的发展和优化,NIPT检测内容有望扩展至三体之外,包括性染色体异常、其他染色体数目及结构异常等。此外,无创单基因遗传病检测和孕妇孕期肿瘤也是NIPT极具发展潜力的方向。近日,Genome Web网站报道了香港中文大学卢煜明教授新技术在单基因遗传病检测上的新突破。

导读 随着技术的发展和优化,NIPT检测内容有望扩展至三体之外,包括性染色体异常、其他染色体数目及结构异常等。此外,无创单基因遗传病检测和孕妇孕期肿瘤也是NIPT极具发展潜力的方向。近日,Genome Web网站报道了香港中文大学卢煜明教授新技术在单基因遗传病检测上的新突破。




无创单基因遗传病检测可以通过对胎儿cfDNA进行目标区域捕获测序,结合父母双方单体型信息,判断胎儿相关疾病的携带情况。近日,Genome Web网站报道了NIPT在单基因遗传病检测上的新突破。

香港中文大学卢煜明教授开发了一种新方法,对父母双方基因组单倍型分型,并对单基因病突变位点附近有效SNP进行区分;通过对母亲外周血DNA进行测序,并应用Relative Haplotype Dosage (RHDO) 分析法推断胎儿是否存在相关遗传突变。

无创单基因遗传病检测新突破

前段时间,香港中文大学卢煜明教授曾在PNAS杂志上发布了第二代无创胎儿基因组分析结果。研究人员通过对母体血浆DNA进行全基因组测序(195×和270×单倍体基因组覆盖),经过一系列生物信息学筛选,成功检测到了胎儿新发突变。此次,卢煜明教授研究团队利用10X Genomics的Linked Read技术和Illumina的测序技术,对父母双方基因组单倍型分型,之后应用母亲外周血DNA分析胎儿是否存在单基因遗传病突变。

胎儿基因组可以分为2部分,一部分遗传自父亲,一部分遗传自母亲。RHDO分析法的原理为,母本DNA以成对染色体形式存在,母本DNA中来自母本父亲DNA与来自母本母亲DNA的比例为1:1。而胎儿DNA会释放一些母本DNA到母亲的血浆中,那么最终将导致原来的1:1失去平衡。2010年,卢煜明教授研究团队正是利用这个原理通过统计算法,开发了Relative Haplotype Dosage (RHDO) 方法来分析胎儿基因组,但该方法在父母基因组单倍型分型方面仍存在缺陷。

10X Genomics公司通过在序列中引入barcode序列,制备出了一种特殊的文库,通过利用Illumina的二代测序,能够得出了跨度在30-100kb的linked reads信息。linked reads使结构变异的检测更加容易。例如,在基因组测序研究中,利用10X Genomics的linked reads技术能检测到一些拷贝数变异,但如果只利用Hiseq全基因组测序数据是无法被发现的。另外,linked reads数据能够鉴别出标准测序数据完全无法鉴定的一个串联重复。

招募临床志愿者


研究人员表示,下一步计划招募上百位志愿者进行临床试验阶段。该技术适用的人群比较广泛,主要有:有单基因遗传病家族史的人群,希望通过无创的方式了解他们的胎儿是否存在相关突变;没有单基因遗传病家族史但为携带者的人群;胎儿超声异常提示可能为某种单基因遗传病所导致的人群。

无创单基因遗传病检测大多数都处在实验室研发阶段,并没有大规模的临床试验验证。目前有针对先天性肾上腺皮质增生、枫糖尿病、地贫等疾病的研究。2014年,《Genetics in Medicine》和Gene上的研究结合靶向测序和NIPT技术,分别开发了检测胎儿枫糖尿病基因型和先天性肾上腺皮质增生基因型的方法。

备注:本文部分内容参考贝瑞和康

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1582609, encodeId=b920158260901, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631047, encodeId=2043163104eba, content=<a href='/topic/show?id=3d99128118f' target=_blank style='color:#2F92EE;'>#NIPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12811, encryptionId=3d99128118f, topicName=NIPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164394, encodeId=6a32164394bd, content=思路不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19061994286, createdName=1e1b1150m51(暂无匿称), createdTime=Tue Dec 20 14:31:03 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164343, encodeId=5614164343ed, content=学了学不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Tue Dec 20 10:54:58 CST 2016, time=2016-12-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1582609, encodeId=b920158260901, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631047, encodeId=2043163104eba, content=<a href='/topic/show?id=3d99128118f' target=_blank style='color:#2F92EE;'>#NIPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12811, encryptionId=3d99128118f, topicName=NIPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164394, encodeId=6a32164394bd, content=思路不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19061994286, createdName=1e1b1150m51(暂无匿称), createdTime=Tue Dec 20 14:31:03 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164343, encodeId=5614164343ed, content=学了学不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Tue Dec 20 10:54:58 CST 2016, time=2016-12-20, status=1, ipAttribution=)]
    2016-12-22 智慧医人
  3. [GetPortalCommentsPageByObjectIdResponse(id=1582609, encodeId=b920158260901, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631047, encodeId=2043163104eba, content=<a href='/topic/show?id=3d99128118f' target=_blank style='color:#2F92EE;'>#NIPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12811, encryptionId=3d99128118f, topicName=NIPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164394, encodeId=6a32164394bd, content=思路不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19061994286, createdName=1e1b1150m51(暂无匿称), createdTime=Tue Dec 20 14:31:03 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164343, encodeId=5614164343ed, content=学了学不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Tue Dec 20 10:54:58 CST 2016, time=2016-12-20, status=1, ipAttribution=)]
    2016-12-20 1e1b1150m51(暂无匿称)

    思路不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1582609, encodeId=b920158260901, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631047, encodeId=2043163104eba, content=<a href='/topic/show?id=3d99128118f' target=_blank style='color:#2F92EE;'>#NIPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12811, encryptionId=3d99128118f, topicName=NIPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Dec 22 01:47:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164394, encodeId=6a32164394bd, content=思路不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19061994286, createdName=1e1b1150m51(暂无匿称), createdTime=Tue Dec 20 14:31:03 CST 2016, time=2016-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=164343, encodeId=5614164343ed, content=学了学不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Tue Dec 20 10:54:58 CST 2016, time=2016-12-20, status=1, ipAttribution=)]
    2016-12-20 圣艮山

    学了学不错

    0

相关资讯

拉斯克奖、引文桂冠奖相继公布,华人科学家卢煜明和张锋有机会获诺奖?

10月3日17时30分,将公布诺贝尔生物学或医学奖获奖名单,距离现在还有11天。 诺贝尔生理学或医学奖,是根据已故的瑞典化学家阿尔弗雷德·诺贝尔的遗嘱而设立的,目的在于表彰在生理学或医学界做出重大贡献的科学家。该奖项于1901年首次颁发,2015年中国药学家屠呦呦获得诺贝尔生物学或医学奖,成为首位获得该奖的中国科学家。 昨日,汤森路透公布了“引文桂冠奖”